2. Inflammation/Immunology

Inflammation/Immunology (炎症/免疫)

Inflammation/Immunology

関連製品

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

製品番号 製品名 CAS 番号 純度 構造式
  • HY-164288
    TDI-6570 2287331-29-5 99.64%
    TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC50 of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the cGAS-STING-IFN signaling pathway, TDI-6570 reduces STING levels and the activation of TBK1, blocks double-stranded DNA-induced cGAS activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases.
    TDI-6570
  • HY-164304
    INF 195 1211379-56-4 99.58%
    INF 195 is an NLRP3 inhibitor. INF 195 can inhibit NLRP3 driven macrophage pyroptosis and IL-1β release, with an EC50 value of 0.15 μM. INF 195 can reduce the infarct size of isolated mouse hearts at low doses, effectively preventing myocardial ischemia/reperfusion injury.
    INF 195
  • HY-168990
    Ontunisertib 2647949-48-0 99.95%
    Ontunisertib (AGMB-129) is an orally active and selective gastrointestinal-restricted ALK5 (TGFβR1) inhibitor. Ontunisertib blocks signalling of the pro-fibrotic TGFβ pathway. Ontunisertib can be used for the research of fibrostenotic Crohn’s disease.
    Ontunisertib
  • HY-19569R
    Upadacitinib (Standard) 1310726-60-3 99.73%
    Upadacitinib (Standard) is the analytical standard of Upadacitinib. This product is intended for research and analytical applications. Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research.
    Upadacitinib (Standard)
  • HY-B2078A
    Eprazinone dihydrochloride 10402-53-6 99.05%
    Eprazinone dihydrochloride is a gent with mucolytic, secretolytic, antitussive, and bronchial antispasmodic properties. Eprazinone dihydrochloride is a neurokinin 1 receptor (NK1R) ligand. Eprazinone dihydrochloride has the potential for chronic bronchitis treatment that improved pulmonary function and arterial partial pressure of oxygen.
    Eprazinone dihydrochloride
  • HY-N0523A
    Gallic acid hydrate

    没食子酸 一水和物

    		5995-86-8 99.98%
    Gallic acid (3,4,5-Trihydroxybenzoic acid) hydrate is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit cyclooxygenase-2 (COX-2). Gallic acid hydrate has various activities, such as antimicrobial, antioxidant, antimicrobial, anti-inflammatory, and anticance activities.
    Gallic acid hydrate
  • HY-N0666C
    L-Aspartic aicd sodium 3792-50-5
    L-Aspartic aicd sodium is an amino acid. L-Aspartic aicd sodium is commonly used for preparing prodrugs to target colon and cecal tissues. L-Aspartic aicd sodium commonly used in the study of inflammatory conditions.
    L-Aspartic aicd sodium
  • HY-N1201R
    Apigenin (Standard) 520-36-5 98.82%
    Apigenin (Standard) is the analytical standard of Apigenin. This product is intended for research and analytical applications. Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.
    Apigenin (Standard)
  • HY-P0172A
    ATI-2341 TFA 98.08%
    ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs).
    ATI-2341 TFA
  • HY-P4127A
    M65 TFA 99.98%
    M65 TFA is a deleted peptide of maxadilan (61 a.a.) with deletion of the residues between positions 24 and 42 and is a specific antagonist of PACAP type 1 receptor that inhibits ANP secretion and can be used for relevant researches.
    M65 TFA
  • HY-P99193
    Enokizumab 909875-08-7 99.23%
    Enokizumab (MEDI-528) is a monoclonal antibody targeting to interleukin (IL)-9. IL-9 regulates the development of airway inflammation, mucus production, airway hyperresponsiveness, and airway fibrosis largely by increasing mast cell numbers and activity in the airways.
    Enokizumab
  • HY-101027A
    GSK4028

    GSK4028

    		2079886-19-2 98.06%
    GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC50 of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.
    GSK4028
  • HY-108882C
    DNase I (filtered) 9003-98-9
    DNase I is an enzyme that degrades DNA. DNase I is mainly produced by digestive system organs, such as the pancreas and parotid gland. Three types of DNase I are known in mammals: pancreatic type, parotid type, and pancreatico-parotid type. DNase I plays a key role in the cleavage of extracellular DNA, and is critical for limiting inflammatory responses and maintaining homeostasis. DNase I is responsible for digesting extracellular nucleoproteins, which may be essential for preventing autoimmune reactions. Decreased DNase I activity may be associated with the occurrence and development of systemic lupus erythematosus (SLE). DNase I (filtered) is filtered through a 0.22 μM membrane and is not tested for pyrogenicity.
    DNase I (filtered)
  • HY-113412A
    3-Methylhistamine dihydrochloride

    3-Methylhistamine (dihydrochloride)

    		36475-47-5 99.80%
    3-Methylhistamine dihydrochloride is a degradation product of histamine. 3-Methylhistamine dihydrochloride, a methylated product of histamine, is associated with immune response and shows upregulation in the vaccinated mice.
    3-Methylhistamine dihydrochloride
  • HY-125859A
    Myeloperoxidase, human white blood cells 9003-99-0
    Myeloperoxidase, human white blood cells (MPO) is a peroxidase. In Myeloperoxidase, human white blood cells mediate oxidative stress by promoting the production of reactive oxygen species (ROS) and active nitrogen (RNS), regulating the polarization and inflammation-related signaling pathways of microglia and neutrophils. Myeloperoxidase, human white blood cells has antibacterial activity.
    Myeloperoxidase, human white blood cells
  • HY-129624A
    Bisindolylmaleimide VIII acetate 138516-31-1 ≥99.0%
    Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective protein kinase C (PKC) inhibitor with an IC50 of 158 nM for rat brain PKC. Bisindolylmaleimide VIII acetate has IC50s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, PKC-ε, respectively. Bisindolylmaleimide VIII acetate facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases.
    Bisindolylmaleimide VIII acetate
  • HY-132607A
    MTL-CEBPA sodium
    MTL-CEBPA (sodium) is the sodium form of MTL-CEBPA (HY-132607). MTL-CEBPA (sodium) is a small activating RNA targeting for upregulation of C/EBPα. MTL-CEBPA (sodium) has anti-inflammatory and anti-cancer activity.
    MTL-CEBPA sodium
  • HY-145603A
    (R)-Vanzacaftor 2374124-48-6 98.02%
    (R)-Vanzacaftor ((R)-VX-121) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator with max activity of 30-60% and EC50 <1 μM in enteroid cells. (R)-Vanzacaftor can be used for the research of cystic fibrosis.
    (R)-Vanzacaftor
  • HY-147216A
    AXKO-0046 dihydrochloride 99.71%
    AXKO-0046 dihydrochloride, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor. AXKO-0046 dihydrochloride has LDHB inhibitory activity with an EC50 value of 42 nM. AXKO-0046 dihydrochloride can be used for the research of cancer metabolism.
    AXKO-0046 dihydrochloride
  • HY-N0390S5
    L-Glutamine-1-13C 159663-16-8 98.0%
    L-Glutamine-1-13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
    L-Glutamine-1-13C
製品番号 製品名 / Synonyms Application Reactivity